Valion Bio, Inc.
VBIO
$2.39
-$0.11-4.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 146.00K | 232.00K | 302.00K | 482.00K | 462.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 146.00K | 232.00K | 302.00K | 482.00K | 462.00K |
| Cost of Revenue | 291.00K | 291.00K | 291.00K | 291.00K | 82.00K |
| Gross Profit | -145.00K | -145.00K | -145.00K | -145.00K | 44.00K |
| SG&A Expenses | 10.20M | 7.51M | 4.77M | 3.27M | 2.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.90M | 12.16M | 7.90M | 5.38M | 4.31M |
| Operating Income | -16.90M | -12.16M | -7.90M | -5.84M | -4.78M |
| Income Before Tax | -18.23M | -12.85M | -7.99M | -5.94M | -4.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.23 | -12.85 | -7.99 | -5.94 | -4.77 |
| Earnings from Discontinued Operations | -523.00K | -733.00K | -885.00K | -385.00K | -385.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.75M | -13.58M | -8.88M | -7.51M | -6.34M |
| EBIT | -16.90M | -12.16M | -7.90M | -5.84M | -4.78M |
| EBITDA | -16.54M | -12.15M | -7.89M | -5.83M | -4.78M |
| EPS Basic | -189.50 | -189.95 | -197.14 | -247.81 | -296.04 |
| Normalized Basic EPS | -111.24 | -108.31 | -110.57 | -95.02 | -127.09 |
| EPS Diluted | -189.50 | -189.95 | -197.14 | -247.81 | -296.04 |
| Normalized Diluted EPS | -111.24 | -108.31 | -110.57 | -95.02 | -127.09 |
| Average Basic Shares Outstanding | 349.50K | 249.60K | 158.10K | 123.40K | 85.20K |
| Average Diluted Shares Outstanding | 349.50K | 249.60K | 158.10K | 123.40K | 85.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |